What is RevealDx?
RevealDx specializes in AI-enabled decision support software designed to improve lung cancer outcomes. The company's flagship technology, which includes the Malignancy Similarity Index (mSI), provides clinicians with quantitative insights to evaluate lung nodules with greater diagnostic confidence. By focusing on non-invasive methodologies, RevealDx addresses a critical gap in pulmonary care, offering a scalable solution that enhances both clinical accuracy and operational efficiency. With FDA clearance already secured, the company is actively expanding its footprint in clinical environments, providing radiologists and pulmonologists with actionable data that supports informed treatment planning and disease monitoring.
How much funding has RevealDx raised?
RevealDx has raised a total of $3.4M across 1 funding round:
Unspecified
$3.4M
Unspecified (2026): $3.4M with participation from 4DMedical
Key Investors in RevealDx
4DMedical
4DMedical is a global medical technology firm specializing in advanced cardiothoracic imaging and AI-driven software that provides deep, quantitative insights into lung function and cardiopulmonary disease.
What's next for RevealDx?
With this major enterprise-level funding, RevealDx is poised to accelerate its commercial expansion and deepen its research and development efforts. The strategic roadmap likely includes scaling the deployment of its mSI platform across broader clinical networks and potentially expanding its diagnostic capabilities to address additional respiratory pathologies. As the company matures, the focus will shift toward long-term clinical validation and the integration of its software into global healthcare systems. By maintaining its commitment to reducing diagnostic costs and improving patient outcomes, RevealDx is well-positioned to capture significant market share in the rapidly evolving landscape of AI-driven medical diagnostics.
See full RevealDx company page